2026
-
Opening Plenary offered insights into therapeutic resistance and innovative approaches to cancer care
Charles L. Sawyers, MD, FAACR, explained that the progression from castration-sensitive to castration-resistant prostate cancer occurs, in part, through a lineage switch that converts prostate cancer cells from an adenocarcinoma cell state to a neuroendocrine state.
-
First Clinical Trials Plenary featured latest precision oncology therapies
Byoung Chul Cho, MD, presented updated results from a phase I/II clinical trial of the next-generation KRAS-G12C inhibitor elisrasib, which was designed for faster and stronger target engagement, to afford sustained inhibition, Cho explained.
-
Second Clinical Trials Plenary highlighted results of next-generation antibody-drug conjugates
Elizabeth K. Lee, MD, presented results from a phase I dose-escalation clinical trial testing a combination of the PARP inhibitor olaparib and the ADC DS-8201a, also known as trastuzumab deruxtecan.
-
Schedule Highlights from the Program Chairs: Monday, April 20
Don’t miss a morning Plenary Session on advances in artificial intelligence, an afternoon address by NCI Director Anthony G. Letai, MD, PhD, FAACR, and more, say Program Committee Chairs Paul S. Mischel, MD, FAACR, and Alice T. Shaw, MD, PhD, FAACR.
-
Tuesday Plenary Session will examine population trends and potential drivers of early-onset cancers
The fourth Plenary Session will integrate population trends, etiologic clues, tumor biology, and real‑world outcomes to discuss potential causes and actionable opportunities for prevention.
-
Meet-the-Expert Sessions return to showcase work from leading researchers
On Monday, two cancer research luminaries will discuss strategies for integrating both molecular and digital pathology and work on how neutrophils are reprogrammed on behalf of cancer within the tumor microenvironment.
-
SABCS session returns to provide overview of breast cancer research updates
A Tuesday session will include specially selected presentations from the most recent San Antonio Breast Cancer Symposium (SABCS), an international forum for foundational discoveries in breast cancer that is cosponsored by the AACR.
-
Discovery Science Plenary discussed cell plasticity and minimal residual disease in solid tumors
During the first Plenary Session on Saturday, Jeanne Tie, MD, spoke about the impact of minimal residual disease (MRD) in guiding clinical trial design for colorectal cancer.
-
2026 Opening Ceremony showcased a year of sustained progress and landmark AACR initiatives
AACR Chief Executive Officer Margaret Foti, PhD, MD (hc), and other speakers highlighted the impressive work of the AACR and its members, as thousands of enthusiastic researchers from around the world gathered to hear the state of the cancer research union.
-
Schedule Highlights from the Program Chairs: Sunday, April 19
Don’t miss the Opening Ceremony and Opening Plenary, the first New Drugs on the Horizon sessions, and more, say Program Committee Chairs Paul S. Mischel, MD, FAACR, and Alice T. Shaw, MD, PhD, FAACR.
